

1 **Brain dopamine responses to ultra-processed milkshakes are highly variable and not**  
2 **significantly related to adiposity in humans.**

3  
4 Valerie L. Darcey<sup>1,2</sup>, Juen Guo<sup>1</sup>, Meible Chi<sup>1</sup>, Stephanie T. Chung<sup>3</sup>, Amber B. Courville<sup>4</sup>, Isabelle  
5 Gallagher<sup>1</sup>, Peter Herscovitch<sup>5</sup>, Paule V. Joseph<sup>6,7,8</sup>, Rebecca Howard<sup>1</sup>, Melissa LaNoire<sup>1</sup>, Lauren  
6 Milley<sup>1</sup>, Alex Schick<sup>1</sup>, Michael Stagliano<sup>1</sup>, Sara Turner<sup>9</sup>, Nicholas Urbanski<sup>1</sup>, Shanna Yang<sup>9</sup>, Nan  
7 Zhai<sup>1</sup>, Megan S. Zhou<sup>1</sup>, Kevin D. Hall<sup>1</sup>

- 8  
9  
10 1. Integrative Physiology Section, National Institute of Diabetes & Digestive & Kidney Diseases,  
11 National Institutes of Health, Bethesda, MD, USA  
12 2. Center on Compulsive Behaviors, Intramural Research Program, NIH, Bethesda, MD, USA  
13 3. Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive, and  
14 Kidney Diseases, National Institutes of Health, Bethesda, MD, USA  
15 4. Human Energy and Body Weight Regulation Core, National Institute of Diabetes & Digestive  
16 & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA  
17 5. Positron Emission Tomography Department, Clinical Center, National Institutes of Health,  
18 Bethesda, MD, USA  
19 6. Section of Sensory Science and Metabolism, National Institute on Alcohol Abuse and  
20 Alcoholism, National Institutes of Health, Department of Health and Human Services,  
21 Bethesda, Maryland, 20892, USA  
22 7. National Institute of Nursing Research, National Institutes of Health, Department of Health  
23 and Human Services, Bethesda, Maryland, 20892, USA  
24 8. National Institute on Deafness and Other Communication Disorders, Smell and Taste  
25 Center, National Institutes of Health, Department of Health and Human Services, Bethesda,  
26 Maryland, 20892, USA  
27 9. Nutrition Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA

28  
29 **CORRESPONDENCE:** Kevin Hall ([kevin.hall@nih.gov](mailto:kevin.hall@nih.gov))

30  
31 ClinicalTrials.gov Identifier: NCT03648892

32  
33  
34 **ABSTRACT**

35 Ultra-processed foods high in fat and sugar may be addictive, in part, due to their purported ability  
36 to induce an exaggerated postingestive brain dopamine response akin to drugs of abuse. Using  
37 standard [<sup>11</sup>C]raclopride positron emission tomography (PET) displacement methods used to  
38 measure brain dopamine responses to addictive drugs, we measured postingestive striatal  
39 dopamine responses to an ultra-processed milkshake high in fat and sugar in 50 young, healthy  
40 adults over a wide body mass index range (BMI 20-45 kg/m<sup>2</sup>). Surprisingly, milkshake  
41 consumption did not result in significant postingestive dopamine response in the striatum ( $p=0.62$ )  
42 nor any striatal subregion ( $p>0.33$ ) and the highly variable interindividual responses were not  
43 significantly related to adiposity (BMI:  $r=0.076$ ,  $p=0.51$ ; %body fat:  $r=0.16$ ,  $p=0.28$ ). Thus,  
44 postingestive striatal dopamine responses to an ultra-processed milkshake were likely  
45 substantially smaller than many addictive drugs and below the limits of detection using standard  
46 PET methods.

## 47 INTRODUCTION

48  
49 Ultra-processed foods often contain high levels of both sugar and fat (Martínez Steele, Baraldi et  
50 al. 2016) – a highly palatable combination that rarely occurs in natural foods (Fazzino, Rohde et  
51 al. 2019). There is a common narrative that such ultra-processed foods may be addictive due to  
52 their consumption eliciting an outsized dopamine response in brain reward regions (Gearhardt,  
53 Bueno et al. 2023), similar to drugs of abuse (Wise and Robble 2020). Furthermore, ultra-  
54 processed foods have been hypothesized to alter the normal gut-brain nutrient sensing pathways  
55 in ways that may enhance their reinforcing effects (Small and DiFeliceantonio 2019).


56  
57 In animal models, brain dopamine responds rapidly to the orosensory properties of food and is  
58 related to palatability (Schultz, Dayan et al. 1997, Hajnal, Smith et al. 2004). Postingestive nutrient  
59 sensing of fat and sugar elicits prolonged dopamine responses primarily in the dorsal striatum via  
60 separate gut-brain pathways (Ferreira, Tellez et al. 2012, Tellez, Medina et al. 2013, Han, Tellez  
61 et al. 2016, Tellez, Han et al. 2016, Fernandes, da Silva et al. 2020) and their combination results  
62 in a synergistic effect (McDougle, de Araujo et al. 2024). Functional MRI work suggests that  
63 similar effects may occur in humans (Stice, Burger et al. 2013, DiFeliceantonio, Coppin et al.  
64 2018), and may be related to adiposity such that blunted responses are observed in people with  
65 obesity (Wang, Tomasi et al. 2014).

66  
67 Whether humans exhibit an exaggerated postingestive brain dopamine response to ultra-  
68 processed foods high in both fat and sugar is unknown, much less whether such a response is  
69 related to adiposity. Therefore, we measured brain dopamine responses to consuming ultra-  
70 processed milkshakes high in both fat and sugar using a standard positron emission tomography  
71 (PET) [<sup>11</sup>C]raclopride displacement method used to investigate drugs of abuse (Volkow, Wang et  
72 al. 1994, Drevets, Price et al. 1999, Cárdenas, Houle et al. 2004, Morris and Yoder 2007). In our  
73 preregistered aims, we hypothesized that striatal dopamine D2-like receptor binding potential  
74 (D2BP) would significantly decrease after milkshake consumption relative to the fasted state,  
75 indicating increased dopamine release displacing the radiotracer from dopamine D2 receptors.  
76 We further hypothesized that postingestive dopamine responses to milkshake consumption would  
77 be negatively correlated with adiposity. Instead, we found that postingestive striatal dopamine  
78 responses were highly variable, not statistically significant, and not significantly related to  
79 adiposity.

## 81 RESULTS

82  
83 A description for this preregistered clinical trial has been described elsewhere (Darcey, Guo et al.  
84 2023). In brief, sixty-one weight stable adults completed 3-5 days of outpatient dietary stabilization  
85 through a eucaloric standardized diet (50% calories from carbohydrate, 35% from fat, 15% from  
86 protein; see **Methods**) provided by the NIH Metabolic Kitchen which was continued into the 5-day  
87 inpatient stay at the NIH Clinical Center which immediately followed (**Table 1, Supplementary**  
88 **Figure 1**). Participants consumed the eucaloric stabilization diet for  $4.5 \pm 1.0$  days outpatient prior  
89 to admission and completed [<sup>11</sup>C]raclopride scanning after  $2.4 \pm 0.9$  days of inpatient  
90 (corresponding to  $6.8 \pm 1.1$  days of total diet stabilization by the time of [<sup>11</sup>C]raclopride scanning).


91



**Supplementary Figure 1. Study design.** Participants (n=50) consumed the provided weight-stabilizing standardized diet for an average of 4.5±1.0 days (mode 5 full days) prior to admission to the NIH Clinical Center for testing. During their inpatient stay, participants continued their dietary stabilization. [11C]Raclopride displacement scan protocol was conducted on pseudo randomly assigned day during inpatient stay (2.4±0.9 days; mode 2 days), after approximately 6.8±1.1 total days (mode 7 full days) of dietary stabilization. Participants completed a confirmed overnight fast (~15 h) at which time hunger was assessed via digital visual analog scale prior to their first [11C]raclopride scan. Upon completion, participants rested quietly in an adjacent room for roughly 75 minutes, at which time they consumed 226mL vanilla milkshake within 5 minutes and began their second and final [11C]raclopride scan approximately 30 minutes after consuming the milkshake. On the final day of their inpatient stay, participants were presented with an ad libitum lunch buffet after a confirmed overnight fast.

92  
93  
94  
95  
96

Data for both fasting and post-milkshake dopamine D2 binding potential (D2BP) are available for n=50 participants (**Supplementary Figure 2**).




**Supplementary Figure 2. Enrollment and data distillation details.** Sixty-one participants provided informed consent for enrollment in this preregistered clinical trial. Only the sample numbers pertinent to the current analysis for primary outcomes are presented here.

97

98 **No significant postingestive striatal dopamine response to an ultra-processed milkshake.**  
99


100 Participants completed the first of two [<sup>11</sup>C]raclopride PET in a confirmed overnight fasted state.  
101 Upon completion of the fasted scan, participants rested quietly in an adjacent room for  
102 approximately 75 minutes, at the end of which they were allotted 5 minutes to consume a vanilla  
103 milkshake (226 mL) (see **Methods**). Participants began their second and final [<sup>11</sup>C]raclopride scan  
104 30 minutes after initiating the milkshake. A paired-samples analysis across the entire sample  
105 revealed that the mean D2BP at fasting was not significantly different from mean D2BP after the  
106 milkshake (whole striatal D2BP fasting 2.9 [0.06 SEM] vs. whole striatal D2BP post-milkshake 2.9  
107 [0.06 SEM];  $p=0.616$ ) (**Figure 1A**). D2BP was not significantly different between fasting and post-  
108 milkshake in any striatal sub-region of interest ( $p$ 's>0.33) (**Supplementary Figure 3**). Further, no  
109 clusters emerged from corresponding voxelwise analyses (see **Supplementary Figure 4** for  
110 unthresholded voxelwise D2BP maps). Whole striatal dopamine response to milkshake did not  
111 significantly differ by sex ( $p=0.207$ ).

112 Given that the only human study to assess temporal dynamics of dopamine responses to  
113 milkshake ingestion suggested that the peak response may occur roughly 20 minutes after  
114 initiating intake (Thanarajah, Backes et al. 2018), we sought to investigate whether we may have  
115 missed an early striatal dopamine response to the ultra-processed milkshake when using the  
116 complete time activity curves collected over the full 70 minute PET session. To address this  
117 possibility, we calculated striatal D2BP from time-activity curves excluding frames from late in the  
118 PET session. Compared to D2BP calculated using the full time-activity curves after the milkshake,  
119 D2BP calculated using only the first 30 minutes of scanning decreased slightly by  $0.06 \pm 0.02$  ( $p$   
120 = 0.006) but was similar to the D2BP decrease using the first 30 minutes of scanning in the fasted  
121 state ( $0.05 \pm 0.03$ ;  $p = 0.13$ ). These negligible differences in striatal D2BP suggest that our  
122 methods likely did not mask a postingestive dopamine signal earlier in the scan time course.




124  
125  
126  
127  
128  
129  
130  
131

**Figure 1.** (A) An ultra-processed milkshake did not significantly impact [ $^{11}C$ ]raclopride binding potential ( $D2BP_{ralco}$ ) across the whole sample ( $n=50$ ) in whole striatum. (B) Distribution of percent change between fasting  $D2BP_{ralco}$  and  $D2BP_{ralco}$  after consumption of milkshake, with individuals displaying dopamine release (green, left, "Responders",  $n=29$ ) and those who did not (purple, right, "Non-responders",  $n=21$ ). (C) Those classified as milkshake "Responders" rated the milkshake as more pleasant (0="neutral", 100="extremely pleasant") (D) and reported greater wanting (0="I don't want any more", 100="I want much more of the milkshake") (E) but similar levels of hunger after an overnight fast compared to "Non-responders".



**Supplementary Figure 3.** An ultra-processed milkshake did not significantly impact [<sup>11</sup>C]raclopride binding potential across the whole sample (n=50) in striatal sub regions of interest: (A) left caudate, (B) right caudate, (C) left putamen, (D) right putamen, (E) left accumbens, (F) right accumbens, (G) left pallidum, and (H) right pallidum.




**Supplementary Figure 4. (A) Response to milkshake across 50 adults.** Unthresholded beta maps contrasting D2BP post-milkshake vs D2BP fasting, using striatal mask. AFNI 3dANOVA2. No clusters survive *a priori* correction for multiple comparisons ( $NN=1$ ,  $k_e=20$ ,  $p_{uncorr}=0.1$ ) (B) **Correlation between BMI and milkshake response ( $\Delta$  D2BP fasting – post-milkshake)** across 50 adults. Unthresholded beta maps. AFNI 3dttest++. No clusters survive *a priori* correction for multiple comparisons ( $NN=1$ ,  $k_e=20$ ,  $p_{uncorr}=0.1$ ).

134 **Adiposity was not significantly correlated with postingestive striatal dopamine responses.**

135  
136 We hypothesized that dopamine responses to the milkshake (percent decrease in D2BP between  
137 post-milkshake and fasting) would be dampened at higher adiposity. BMI tended to be weakly  
138 related to dopamine response such that leaner individuals had a slightly greater decrease in D2BP  
139 percent change from fasting (whole striatum D2BP,  $r=0.276$ ,  $p=0.052$ ; **Supplementary Figure**  
140 **4**). However, this relationship was not robust to influential data points (robust regression  $r=0.076$ ,  
141  $p=0.507$ ; **Supplementary Figure 5**) and no clusters emerged from corresponding voxelwise  
142 analyses correlating BMI and milkshake response ( $\Delta$ D2BP [milkshake – fasting]) (see  
143 **Supplementary Figure 4B** for unthresholded voxelwise maps). Furthermore, neither kilograms  
144 of fat mass ( $r=0.219$ ,  $p=0.126$ ,  $n=50$ ), body fat percentage ( $r=0.155$ ,  $p=0.282$ ,  $n=50$ ), age  
145 ( $r=0.139$ ,  $p=0.337$ ,  $n=50$ ), fasting glucose ( $r=0.159$ ,  $p=0.280$ ,  $n=48$ ), fasting insulin ( $r=0.137$ ,  
146  $p=0.360$ ,  $n=47$ ), nor insulin sensitivity (HOMA-IR;  $r=0.112$ ,  $p=0.459$ ,  $n=46$ ) were correlated with  
147 whole striatal dopamine response to the post-ingestive milkshake state.

148  
149 While the milkshake was provided as the same absolute amount to all participants (418kcal), this  
150 amount varied as a proportion of each participant's resting energy expenditure (REE).  
151 Nevertheless, milkshake energy intake adjusted for REE was not significantly related to the  
152 striatal dopamine response (% of REE;  $r= -0.175$ ,  $p=0.228$ ,  $n=49$ ).





**Supplementary Figure 5.** Relationships between BMI and response to milkshake (% change D2BP from fasting) across (A) whole striatum and striatal subregions (B – I) are not robust to influential data points.

154 **Postingestive striatal dopamine responses may be related to perceived hunger and**  
155 **hedonic responses to the milkshake.**

156  
157 To explore correlates of the highly variable interindividual dopaminergic response to the ultra-  
158 processed milkshake (**Figure 1B**) we investigated features that distinguished those who  
159 demonstrated a dopamine response in the expected direction (“Responders”) compared to those  
160 who demonstrated an increase in D2BP after milkshake, opposite to that expected (“Non-  
161 responders”) (**Table 2**).

162  
163 “Responders” perceived the milkshake to be more pleasant (73.3 [4.1] vs 48.2[8.0],  $p=0.010$ ),  
164 they wanted more of the milkshake (56.4[6.4] vs 25.8[6.8]  $p=0.003$ ) and tended to be hungrier in  
165 the overnight fasted state (55.7[5.1] vs 41.3[7.4],  $p=0.106$ ) as compared to the “Non-Responders”  
166 (**Figure 1C-E; Table 2**). Furthermore, “Non-responders” tended to report an increase in perceived  
167 hunger after the milkshake compared to “Responders” (**Table 2**). Both groups indicated similar  
168 preferences for fat ( $p=0.271$ ) and sweet ( $p=0.576$ ) tastes (**Table 1**) and similarly considered the  
169 milkshake to have “met expectations” ( $p=0.365$ ; **Table 2**).

170  
171 Across the group as a whole, there were no significant correlations between whole striatal  
172 dopamine response and degree to which the milkshake met expectations ( $r=-0.064$ ,  $p=0.681$ ,  
173  $n=43$ ), perceived milkshake pleasantness ( $r=-0.194$ ,  $p=0.201$ ,  $n=45$ ), or wanting more milkshake  
174 ( $r=-0.237$ ,  $p=0.126$ ,  $n=43$ ). Further, these relationships were also not evident in striatal ROI  
175 subregions ( $p$ 's  $>0.111$ , not shown).

176  
177 While perceived hunger after an overnight fast was not significantly related to adiposity (BMI:  $r=-$   
178  $0.185$ ,  $p=0.223$ ,  $n=45$ ; Percent body fat:  $r=-0.030$ ,  $p=0.844$ ,  $n=45$ ), hunger level was weakly  
179 related to whole striatal dopamine response to milkshake ( $r=0.288$ ,  $p=0.055$ ,  $n=45$ ) driven largely  
180 by responses in the right caudate ( $r=0.311$ ,  $p=0.037$ ), right pallidum ( $r=-0.309$ ,  $p=0.039$ ) and left  
181 putamen ( $-0.390$ ,  $p=0.008$ ) (**Figure 3A**). These regional associations were largely supported by  
182 voxelwise analyses (**Figure 3B**), revealing clusters in the left putamen and right caudate where  
183 the magnitude of milkshake response is correlated with perceived hunger after an overnight fast  
184 (**Supplementary Table 1** for cluster details). The change in hunger between the fasted and post-  
185 milkshake states correlated with whole striatal dopamine response to the milkshake ( $r=0.393$ ,  
186  $p=0.019$ ,  $n=35$ ) such that the more hunger was suppressed by the milkshake, the greater the  
187 degree of observed dopamine release. This effect is largely driven by dorsal rather than ventral  
188 striatal ROIs.

**Supplementary Table 1. Locations of striatal clusters with significant correlations.** PET resolution 3.5mm<sup>3</sup>. Imaging analyses conducted in Analysis of Functional Neuroimaging (AFNI) within striatal region binding potential mask. Clusters defined by voxels with faces touching, cluster extent of 20, bi-sided  $p_{uncorr} < 0.1$ .

	Location of peak			Voxels	Size (mm <sup>3</sup> )	t-stat	alpha
	x	y	z				
$\Delta$ D2BP (Post milkshake – Fasting) <sup>(a)</sup>							
<i>No clusters</i>	--	--	--	--	--	--	--
$\Delta$ D2BP x BMI <sup>(b)</sup>							
<i>No clusters</i>	--	--	--	--	--	--	--
$\Delta$ D2BP x Fasting Hunger <sup>(c)</sup>							
Left putamen	22.8	-6.0	13.5	106	4545	-2.44	<0.01
Right caudate	-15.8	-20.0	6.5	39	1672	-2.46	<0.05
Right putamen	-33.2	11.5	-0.5	25	1072	2.53	>0.10
Right pallidum	-15.8	-2.5	-0.5	20	858	-2.69	>0.10
$\Delta$ D2BP x Ad Libitum Total Energy Intake <sup>(d)</sup>							
Left putamen	26.2	-2.5	3.0	33	1415	-3.74	>0.05
$\Delta$ D2BP x Ad Libitum Non-cookie Energy Intake <sup>(d)</sup>							
<i>No clusters</i>	--	--	--	--	--	--	--
$\Delta$ D2BP x Ad Libitum Cookie Energy Intake <sup>(d)</sup>							
Left putamen	29.8	11.5	6.6	41	1757	-2.85	<0.02
Right putamen	-26.2	11.5	6.5	34	1458	-2.52	0.05


a. Paired samples t-test, n=50

b. 1 sample t-test, n=50

c. 1 sample t-test, n=45

d. 1 sample t-test, n=45

189  
 190 The milkshake increased blood glucose and insulin at both 30 minutes and 90 minutes post-  
 191 milkshake, but neither the overall increase in glucose nor insulin, nor rates of increases were  
 192 correlated with the milkshake dopamine responses at the whole striatal or sub-striatal ROI levels  
 193 (not shown). Furthermore, we did not observe significant differences in either postprandial  
 194 glucose or insulin changes between “Responders” and “Non-responders” (**Supplementary**  
 195 **Figure 5**).



196  
 197 **Figure 3. Post-ingestive dopamine responses to milkshake correlated with prior fasting hunger and subsequent ad libitum**  
 198 **cookie energy intake.** (A) Region of interest (ROI) analyses indicate that self-reported hunger after an overnight fast correlated with  
 199 dopamine response to milkshake consumption, particularly in the left putamen. (B) The ROI relationship between hunger and dopamine  
 200 response, was supported by voxelwise correlation analysis which identified two clusters surviving correction for multiple comparisons  
 201 (left putamen: 106 voxels;  $x = 22.8$ ,  $y = -6.0$ ,  $z = 13.5$ ;  $p < 0.01$ ; and right caudate: 39 voxels;  $x = -15.8$ ,  $y = -20.0$ ,  $z = 6.5$ ;  $p < 0.05$ ). (C)  
 202 Additionally, ROI analyses indicate that the post-ingestive dopamine response to milkshake particularly in the left putamen was  
 203 correlated with ad libitum intake of energy from cookies at a subsequent meal test in the overnight fasted state. (D) Voxelwise analyses  
 204 identified clusters in bilateral putamen surviving correction for multiple comparisons where dopamine response was correlated with  
 205 subsequent ad libitum cookie consumption (left putamen: 41 voxels,  $x = 29.8$ ,  $y = 11.5$ ,  $z = 6.6$ ;  $p < 0.02$ ; right putamen: 34 voxels,  $x = -$   
 206  $26.2$ ,  $y = 11.5$ ,  $z = 6.5$ ;  $p = 0.05$ ). All clusters defined by  $NN=1$  (faces touching),  $k_e=20$ , bi-sided  $p_{uncorr} < 0.1$ , and cluster corrected at  $p < 0.05$ .

207 Table 1. Participant characteristics and group differences between milkshake “responders” and “non-responders” at the whole striatum  
 208 level **Participant characteristics and group differences between participants demonstrating a postingestive decrease in D2BP**  
 209 **as a result of milkshake (“Responders”) and those demonstrating an increase in D2BP (“Non-responders”). Means and standard**  
 210 **deviations indicated.**

	Enrolled participants (n)	Enrolled participants	Milkshake Completers (n)	Milkshake Completers	Milkshake “Responders” (n)	Milkshake “Responders”	Milkshake “Non-responders” (n)	Milkshake “Non-responders”	p (Responders vs. Non-responders)
<b>Total N</b>	61		50		29		21		
<i>Females</i>	40	65%	38	66.7%	19	65.5%	14	66.7%	0.933
<b>Race</b>									0.741
<i>Black</i>	32	52.5%	27	54.0%	15	51.7%	12	57.1%	
<i>White</i>	18	29.5%	15	30.0%	10	34.5%	5	23.8%	
<i>Asian</i>	7	11.5%	5	10.0%	3	10.3%	2	9.5%	
<i>Other/Multiple</i>	4	6.6%	3	6.0%	1	3.4%	2	9.5%	
<b>Age (years)</b>	61	32.2 ± 7.2	50	31.9 ± 7.2	29	30.8 ± 7.5	21	33.4 ± 6.8	0.218
<b>Body weight (kg)</b>									
<i>Mean</i>	61	85.9 ± 25.3	50	86.1 ± 25.0	29	84.6 ± 23.1	21	88.2 ± 27.7	0.622
<i>Range</i>	61	45.9 – 148.6	50	45.9 – 148.6	29	57.2 – 148.6	21	45.9 – 133.9	
<b>Body fat (%)</b>									
<i>Mean</i>	61	35.0 ± 12.6	50	35.1 ± 12.3	29	35.9 ± 11.5	21	33.9 ± 13.6	0.571
<i>Range</i>	61	11.3 – 59.0	50	11.3 – 52.4	29	12.1 – 52.4	21	11.3 – 51.2	
<b>BMI (kg/m<sup>2</sup>)</b>									
<i>Mean</i>	61	30.1 ± 8.2	50	30.2 ± 7.9	29	29.5 ± 7.2	21	31.0 ± 8.9	0.540
<i>Range</i>	61	20.3 – 52.8	50	20.3 – 44.8	29	20.3 – 44.4	21	20.5 – 44.8	
<b>Resting energy expenditure (kcal/day)</b>	60	1624 ± 319	49	1626 ± 321	29	1607 ± 299	20	1655 ± 357	0.608
<b>Glucose, fasting (mg/dL)</b>	55	91.8 ± 7.7	48	92.8 ± 7.3	27	93.0 ± 7.5	21	92.5 ± 7.2	0.826
<b>Insulin, fasting (μU/mL)</b>	54	12.6 ± 7.4	47	12.6 ± 7.0	28	13.0 ± 7.8	19	12.1 ± 5.6	0.689

<b>HOMA-IR</b>	52	2.9 ± 1.9	46	2.9 ± 1.8	27	3.1 ± 2.1	19	2.8 ± 1.3	0.563
<b>Habitual diet (Food Frequency Questionnaire)</b>									
<i>Usual energy intake (kcal/day)</i>	52	1497 ± 662	45	1481 ± 642	28	1464 ± 664	17	1510 ± 622	0.821
<i>Protein (% kcal)</i>	52	15.7 ± 4.2	45	15.7 ± 4.2	28	15.5 ± 3.3	17	16.0 ± 5.5	0.697
<i>Fat, total (%kcal)</i>	52	33.0 ± 8.2	45	33.3 ± 8.1	28	33.6 ± 6.6	17	32.7 ± 10.5	0.709
<i>Saturated fat (%kcal)</i>	52	10.5 ± 3.0	45	10.5 ± 3.1	28	10.9 ± 2.8	17	9.8 ± 3.6	0.256
<i>Fatty acid ratio (unsat:sat)</i>	52	1.9 ± 0.4	45	2.0 ± 0.4	28	1.9 ± 0.3	17	2.1 ± 0.4	0.032
<i>Carbohydrate, total (% kcal)</i>	52	51.6 ± 11.7	45	51.2 ± 11.7	28	50.5 ± 9.5	17	52.4 ± 14.8	0.641
<i>Added sugars (grams)</i>	52	47.0 ± 40.3	45	46.1 ± 39.7	28	43.4 ± 37.0	17	50.5 ± 44.7	0.562
<b>Taste Preferences</b>									
<i>Fat taste preference (% milkfat; w/v)</i>	49	11.1 ± 6.0	41	11.6 ± 6.5	24	10.6 ± 5.4	17	12.9 ± 7.7	0.271
<i>Sweet taste preference (g sucrose/1000mL water)</i>	51	11.9 ± 9.1	42	12.6 ± 9.1	25	12.0 ± 8.5	17	13.6 ± 10.0	0.576
<b>Three Factor Eating Questionnaire</b>									
<i>Cognitive Restraint</i>	61	8.3 ± 4.7	59	8.5 ± 4.6	29	8.8 ± 4.0	21	8.1 ± 5.3	0.617
<i>Disinhibition</i>	61	4.8 ± 2.7	50	5.0 ± 2.8	29	5.3 ± 2.7	21	4.4 ± 2.8	0.256
<i>Hunger</i>	61	3.2 ± 2.6	50	3.4 ± 2.7	29	3.3 ± 2.9	21	3.5 ± 2.5	0.799
<b>Yale Food Addiction Scale</b>									
<i>Continuous Symptom Count</i>	60	1.1 ± 1.0	48	1.1 ± 0.9	29	1.2 ± 1.1	19	1.0 ± 0.7	0.293

212 Table 2. **Group differences between participants demonstrating a decrease in whole striatal D2BP as a result of milkshake**  
 213 **(“Responders”) and those demonstrating an increase in D2BP (“Non-responders).** Means and standard errors reported.  
 214

	<b>Milkshake Completers (n)</b>	<b>Milkshake Completers [Mean (SEM)]</b>	<b>Milkshake “Responders” (n)</b>	<b>Milkshake “Responders” [Mean (SEM)]</b>	<b>Milkshake “Non- responders” (n)</b>	<b>Milkshake “Non responders” [Mean (SEM)]</b>	<b>p (Responders vs. Non- responders)</b>
<b>D2BP % Change, Whole Striatum (Milkshake – Fasting)</b>							
<i>Mean percent change</i>	50	1.1(1.3)	29	-4.3(0.73)	21	8.5(2.0)	<0.0001
<i>Range</i>	50	-18.1 – 37.7	29	-18.1 – -0.9	21	0.03 – 37.7	
<b>Milkshake ratings</b>							
<i>Pleasantness</i>	45	63.3 (4.4)	27	73.3 (4.1)	18	48.2 (8.0)	0.010
<i>Wanting more</i>	43	44.3 (5.2)	26	56.4 (6.4)	17	25.8 (6.8)	0.003
<i>Met expectations</i>	43	57.0 (4.1)	26	60.1 (5.4)	17	52.4 (6.4)	0.365
<b>Hunger ratings</b>							
<i>After overnight fast</i>	45	49.3 (4.4)	25	55.7 (5.1)	20	41.3 (7.4)	0.106
<i>Effect of milkshake (% change from fasting)</i>	35	16.9 (13.9)	20	-8.4 (8.6)	15	50.8 (28.7)	0.065
<b>Ad libitum energy intake (REE-adjusted)</b>							
<i>Total (kcal)</i>	45	956.7 (70.3)	28	1007.0 (76.8)	17	873.8 (137.4)	0.364
<i>Cookie-only (kcal)</i>	45	109.9 (19.0)	28	134.1 (23.6)	17	69.9 (30.2)	0.102
<i>Non-cookie (kcal)</i>	45	846.3 (58.9)	28	872.9 (64.3)	17	803.8 (116.5)	0.575
<b>Glycemic response to milkshake</b>							
<i>Glucose</i>							
90-minute weighted average (mg/dL)	44	99.8 (1.3)	25	99.0 (1.5)	19	100.8 (2.3)	0.506
Change, 0 min – 30 min (mg/dL)	46	3.4 (1.4)	26	4.0 (1.6)	20	2.7 (2.3)	0.640

Change, 30 min – 90 min (mg/dL)	45	11.5 (2.6)	26	7.0 (2.8)	19	17.6(4.4)	0.041
Peak, 0 min – 90 min (mg/dL)	44	110.7 (2.1)	25	107.4(2.2)	19	115.4(3.8)	0.094


*Insulin*

90-minute weighted average (μU/mL)	36	36.1 (4.4)	23	38.2 (6.6)	13	32.6 (3.8)	0.468
Change, 0 min – 30 min (μU/mL)	43	26.5 (5.4)	25	31.1 (8.9)	18	20.1 (4.0)	0.267
Change, 30 min – 90 min (μU/mL)	36	-5.0 (5.8)	23	-10.2 (7.8)	13	4.1 (7.9)	0.239
Peak, 0 min – 90 min (μU/mL)	36	52.0 (6.5)	23	53.6 (9.9)	13	49.1 (5.2)	0.689

---



216



**Supplementary Figure 5. Glycemic and insulinemic response to milkshake.** Overall, milkshake caused a significant increase from fasting levels of both glucose ( $F=27.0$ ,  $p<0.001$ ,  $n=44$ ) and insulin ( $F=25.4$ ,  $p<0.001$ ,  $n=36$ ) over the duration of the scan. However, the interaction between time and dopamine response (group) was not significant for either glucose ( $F=2.2$ ,  $p=0.125$ ,  $n=44$ ) or insulin responses ( $F=0.75$ ,  $p=0.480$ ,  $n=36$ ). Error bars represent standard error.

217  
218  
219  
220  
221  
222  
223  
224

**Postingestive dopamine responses correlated with *ad libitum* intake of ultra-processed cookies high in fat and sugar.**

On their last inpatient day, participants were offered an *ad libitum* buffet (**Supplementary Figure 6**) in metabolic state similar to that of milkshake ingestion on a previous day and were instructed to eat as much or as little as they desired. Energy consumed (kcal) was calculated after remaining

225 food was weighed back by Metabolic Kitchen staff. Exploratory analyses of energy intake are  
226 adjusted by resting energy expenditure (REE) measured during the inpatient stay.  
227



**Supplementary Figure 6. Ad libitum buffet array offered for lunch (~12:00pm) after an overnight fast on the day of their discharge.** Participants were presented with the above meal (>6000 kcal, 35% carbohydrate, 17% protein, 48% fat) and instructed to consume as much or as little as they wanted. Each food was weighed before and after consumption to determine total nutrient intake. Participants were presented with: 8 slices of Ultimate Grains Whole Wheat Bread, 250g roast beef deli meat, 250g turkey deli meat, 220g Glenview Farms Swiss Cheese, 220g Glenview Farms American cheese, 200g sliced tomatoes, 200g green leaf lettuce, 200g grapes, 18 Chips Ahoy! chocolate chip cookies, 135g Hellmann's Real mayonnaise, 135g Monarch yellow mustard, 375g Pasado mild salsa, 200g baby carrots, 180g Tostito tortilla chips, and 850g water. (Bread and cookies were weighed before array administration and the weight was recorded in grams.)

228  
229  
230 REE-adjusted total energy intake was not correlated with dopamine response to milkshake across  
231 the striatum as a whole ( $r=-0.205$ ,  $p=0.176$ ) but tended to be weakly correlated with postingestive  
232 dopamine response again in the left putamen ( $r=-0.279$ ,  $p=0.064$ ).  
233

234 We separated energy intake from the sole high-fat, high-sweet ultra-processed food item offered  
235 at the meal test, chocolate chip cookies (REE-adjusted cookie energy intake, "cookie EI"), from  
236 energy consumed from other foods (REE-adjusted non-cookie energy intake, "non-cookie EI").  
237 While non-cookie EI was not related to dopamine response to milkshake in any striatal ROI ( $p$ 's  
238 > 0.131), cookie EI specifically tended to weakly correlate with whole striatal ( $r=-0.283$ ,  $p=0.06$ )  
239 and left caudate ( $r = -0.276$ ,  $p=0.067$ ) response and was significantly correlated with dopamine  
240 response in the left pallidum ( $r = -0.332$ ,  $p=0.026$ ) and again in the left putamen ( $r = -0.323$ ,  
241  $p=0.031$ ) (**Figure 3C**).  
242

243 Voxelwise analyses support the ROI analyses, revealing bilateral clusters in the putamen where  
244 the magnitude of milkshake response is correlated with REE-adjusted *ad libitum* cookie energy  
245 intake (**Figure 3D**; cluster information in **Table 3**.)

## 246 247 **DISCUSSION**

248  
249 Contrary to our hypotheses, we did not find evidence for a significant average increase in post-  
250 ingestive striatal dopamine in response to consuming ultra-processed milkshakes high in fat and  
251 sugar. Furthermore, interindividual variation in the postingestive dopamine response was not  
252 significantly related to adiposity. Instead, our exploratory analyses suggest that post-ingestive  
253 dopamine response variability between people may be related to perceived hunger, hedonic  
254 responses, and may predict future ultra-processed food eating behaviors.

255  
256 Our study was designed to elicit a post-ingestive dopamine response as well as minimize several  
257 sources of variability by delivering a single exposure to a novel milkshake formulation that  
258 participants experienced as a non-random, unconditioned stimulus at the time of PET scanning  
259 after a confirmed, standardized overnight fast following a period of controlled feeding in weight  
260 stable adults. This design minimized psychological and behavioral influences (e.g., pre-exposure  
261 (Burger and Stice 2012), cue-expectation (Wang, Wiers et al. 2019)) as well as variability in  
262 physiological state (Stice, Yokum et al. 2010, Chen and Zeffiro 2020).

263  
264 The [<sup>11</sup>C]raclopride PET displacement method used in our study (Endres, Kolachana et al. 1997,  
265 Laruelle, Iyer et al. 1997) has high reproducibility (Doudet and Holden 2003), with test-retest  
266 absolute D2BP differences in the striatum of ~6% (Nordström, Farde et al. 1992, Volkow, Fowler  
267 et al. 1993, Hirvonen, Aalto et al. 2003). This method has been regularly used to measure  
268 significant mean striatal dopamine responses following ingestion of substances with the greatest  
269 potential for abuse and addiction such as psychostimulants that produce ~10-20% decreases in  
270 mean striatal D2BP (Volkow, Wang et al. 1994, Cárdenas, Houle et al. 2004, Tomasi, Manza et  
271 al. 2023). However, relatively large increases in extracellular dopamine, as documented by  
272 simultaneous microdialysis measurements (Breier, Su et al. 1997, Tsukada, Nishiyama et al.  
273 1999, Harada, Nishiyama et al. 2002, Schiffer, Volkow et al. 2006) are required to detect acute  
274 displacement of [<sup>11</sup>C]raclopride in the striatum using PET. Thus, the ultra-processed milkshake  
275 may have resulted in striatal dopamine responses that were simply too small to reliably detect  
276 using the standard [<sup>11</sup>C]raclopride PET method and may be closer in magnitude to that of nicotine  
277 – a drug widely acknowledged to promote addiction (Benowitz 2010), that only produces ~5%  
278 reduction in striatal D2BP (Marenco, Carson et al. 2004) and some studies have failed to show a  
279 significant effect of nicotine (Chukwueke and Le Foll 2019).

280  
281 In other words, despite expecting the high fat and sugar formulation of the ultra-processed  
282 milkshake to produce a synergistic effect on striatal dopaminergic activity (DiFeliceantonio,  
283 Coppin et al. 2018, McDougale, de Araujo et al. 2024), our data suggest that any extracellular  
284 dopamine responses following milkshake consumption were smaller than those following  
285 ingestion of drugs of abuse. Thus, the narrative that ultra-processed foods high in fat and sugar  
286 can be as addictive as drugs of abuse based on their potential to elicit an outsized dopamine  
287 response in brain reward regions was not supported by our data.

288  
289 Contrary to our results, previous smaller studies using [<sup>11</sup>C]raclopride displacement PET have  
290 shown significant decreases in postingestive striatal D2BP. A classic study of 7 people without  
291 obesity showed that consuming a favorite mixed meal decreased D2BP in the dorsal striatum  
292 (Small, Jones-Gotman et al. 2003). In a study of 11 people using an 8oz milkshake nearly identical  
293 in macronutrient composition to the present study, decreased D2BP was observed in regions of

294 the striatum, and this was driven predominantly by 5 participants without obesity (Carnell, Steele  
295 et al. 2023). Differences in post-ingestive striatal dopamine response between glucose versus  
296 sucralose beverages in 19 adults were found to be negatively related to body mass index, but no  
297 significant overall differences in D2BP between the beverages were reported (Wang, Tomasi et  
298 al. 2014). In 10 individuals with obesity, no significant difference in D2BP was found between  
299 satiated and fasted conditions and the authors suggested that obesity could blunt the post-  
300 ingestive dopamine response (Eisenstein, Black et al. 2020). We believe our null results in 50  
301 adults suggest that previous findings of post-ingestive striatal dopamine responses in studies with  
302 substantially smaller numbers of subjects may have been due to type 1 statistical error.

303  
304 Recently, a rapid orosensory dopamine response followed by a later post-ingestive response were  
305 observed in a study using a novel [<sup>11</sup>C]raclopride PET procedure in 10 adults who sipped  
306 milkshakes at random intervals via a gustometer over a 10 minute period during a 60 minute scan  
307 (Thanarajah, Backes et al. 2018). Perhaps our lack of ability to measure a dopamine response to  
308 the milkshake using a standard [<sup>11</sup>C]raclopride PET procedure was because the post-milkshake  
309 PET scan started 30 minutes after the milkshake was consumed. However, we believe this is  
310 unlikely because brief intragastric nutrient infusions in rodents produce long lasting (~hours)  
311 striatal dopamine responses (Tellez, Medina et al. 2013, Tellez, Han et al. 2016, McDougale, de  
312 Araujo et al. 2024) and the milkshake used in our study would be expected to result in a relatively  
313 constant gastric emptying rate given that the milkshake contained appreciable amounts of cream  
314 and whole milk (Okabe, Terashima et al. 2015) with ongoing gut nutrient sensing over the duration  
315 of the subsequent 75-minute PET scan. Nevertheless, if the peak post-prandial dopamine  
316 response was early and dissipated by the end of the scan, then calculating binding potential using  
317 time-activity curves over the entire duration of the scan may have attenuated the effect of the  
318 milkshake on the calculated D2BP. However, truncating the PET time-activity curves to a  
319 minimum of 30 minutes had no appreciable effect on our results.

320  
321 Our data suggest that the variable post-ingestive dopamine responses to the ultra-processed  
322 milkshake were unrelated to adiposity. This was surprising because animal studies suggested  
323 that diet induced obesity blunts dopamine response to nutrients in the gut (Johnson and Kenny  
324 2010) and human functional MRI work suggested that obesity blunts striatal activity to food  
325 consumption (Stice, Spoor et al. 2008). A recent metabolic imaging study using SPECT observed  
326 that in both people with and without obesity, while nasogastric delivery of sugar caused dopamine  
327 release, the post-ingestive dopamine response to fat-alone was only significant in those without  
328 obesity (van Galen, Schrantee et al. 2023), though the groups were not statistically compared.

329  
330 A limitation of our study was that we enrolled only participants free from a history of disordered  
331 eating or addiction and we found minimal endorsement of behaviors consistent with the construct  
332 of food addiction. Food addiction is reported to have a 14% prevalence in non-clinical adult  
333 samples (Praxedes, Silva-Júnior et al. 2022) and is comorbid with binge eating disorder (Carbone,  
334 Aloï et al. 2023) which has been associated with altered dopamine signaling specifically  
335 anticipatory dorsal striatal dopamine release to food cues, independent of adiposity (Wang et al.,  
336 2011). It is interesting to speculate that the post-ingestive striatal dopamine response to an ultra-  
337 processed food high in fat and sugar may be more pronounced in those endorsing behavioral  
338 features of “food addiction” or receiving a clinical diagnosis of binge eating disorder.

339  
340 Even in the absence of a clinical eating disorder or food addiction, it is possible that some  
341 individuals may experience large post-ingestive dopamine responses to ultra-processed foods  
342 high in both fat and sugar under some conditions. Our exploratory analyses indicated that  
343 individual variability in post-ingestive striatal dopamine responses may be related to the degree of  
344 hunger in the fasted state. Some of our study participants displayed dopamine responses to the

345 post-ingestive signals from milkshake in the putamen, consistent with post ingestive component  
346 in other studies (Thanarajah, Backes et al. 2018) who displayed the expected response to  
347 milkshake consistently in left putamen, encompassing a region where interoceptive signals are  
348 registered (Pauli, O'Reilly et al. 2016). Inducing hunger via restricted food access enhances  
349 development of addiction to drugs in animal studies (Carroll 1985), possibly by enhancing  
350 postingestive dopamine responses.

351  
352 We believe the most likely interpretation of our data is that consuming an ultra-processed  
353 milkshake high in fat and sugar produces small, but highly variable, changes in postingestive  
354 striatal dopamine that were unrelated to adiposity but possibly related to perceived hunger and  
355 hedonic responses. Furthermore, individual postingestive striatal dopamine responses may  
356 predict food choices given that they correlated with ad libitum consumption of ultra-processed  
357 cookies high in both fat and sugar, which were the only such items available in a buffet lunch. Our  
358 results do not discount the experience of individuals who report difficulty in controlling their intake  
359 of ultra processed foods high in fat and sugar, but rather calls into question the narrative that  
360 postingestive striatal dopamine responses similar in magnitude to illicit drugs perpetuate  
361 consumption of ultra-processed foods and promote their excess intake (Hall, Ayuketah et al.  
362 2019).

363  
364 **AUTHOR CONTRIBUTIONS**  
365 VLD, PH and KDH designed the research study. ABC, PVJ, ST, SY, and STC contributed to  
366 research design, data collection and analysis. MC, IG, RH, ML, LM, AS, MSS, NU, NZ, MSZ  
367 conducted experiments and collected data. VLD and JG analyzed data and performed statistical  
368 analysis. VLD and KDH drafted the manuscript. All authors contributed intellectually and approved  
369 the manuscript.

370  
371 **ACKNOWLEDGEMENTS**  
372 This work was supported by the Intramural Research Program of the National Institutes of Health,  
373 National Institute of Diabetes and Digestive and Kidney Diseases and by *the NIH Center on*  
374 *Compulsive Behaviors via the NIH Shared Resource Subcommittee*. We thank the PET  
375 Department staff and technologists, nursing and nutrition staff at the NIH Metabolic Clinical  
376 Research Unit for their invaluable assistance with this study. We thank Dr. Gene Jack Wang and  
377 Dr. Dana Small for their helpful comments on our results and Mr. Christopher Colvin for assistance  
378 with figure preparation. We are most thankful to the study subjects who volunteered to participate  
379 in this demanding protocol.

380  
381 **METHODS**  
382 Sixty-one adults provided informed consent to participate in a dual PET radiotracer study  
383 investigating the relationship between D2R availability and BMI under controlled dietary  
384 conditions (ClinicalTrials.gov NCT03648892). Participants were recruited from the community  
385 over a wide BMI range and approximately evenly sampled in each of three BMI categories ( $18.5$   
386  $\text{kg/m}^2 \leq \text{BMI} < 25 \text{ kg/m}^2$ ,  $25 \text{ kg/m}^2 \leq \text{BMI} < 35 \text{ kg/m}^2$ ,  $\text{BMI} \geq 35 \text{ kg/m}^2$ ) to ensure sufficient BMI  
387 range to test the quadratic hypothesis. Eligible volunteers were English-speaking, weight stable  
388 (less than  $\pm 5\%$  change in the past month), between 18-45 years of age,  $\text{BMI} \geq 18.5 \text{ kg/m}^2$ . They  
389 had no history of bariatric surgery, metabolic disorders, previous traumatic head injury or  
390 neurological disorders, severe food allergies (e.g., dairy, gluten) impaired activities of daily living,  
391 high blood pressure ( $>140/90$  mm Hg), or current use of medication influencing metabolism or  
392 psychiatric medications. They did not have psychiatric conditions or disordered eating (EDE-Q,  
393 DSM Cross Cutting Symptom Measure Self Rated Level 1), nicotine dependence, drug use or in  
past 12 months (confirmed via urine toxicology at screening visit), binge drinking over previous 6

394 months, excessive caffeine consumption, or safety contraindications to MRI. Females were  
395 excluded if they were pregnant or lactating.

396  
397 In the full sample (n=61), women reporting regular menses (not using hormonal contraceptives)  
398 (n=31), started inpatient admissions on day  $17.4 \pm 9.9$  of their cycle. Participants self-identified  
399 race and ethnicity at the time of admission to the NIH Clinical Center. Handedness was not  
400 exclusionary. Participants completed the 10-item Edinburgh Handedness questionnaire to  
401 determine laterality quotient (Oldfield 1971) and 96.7% of participants (n=59) were determined to  
402 be right-handed (laterality quotient >0).

#### 403 404 **Method Details**

405 This study was conducted between September 26, 2018 and February 17, 2023. On average,  
406 [ $^{11}\text{C}$ ]raclopride scans were completed after  $6.8 \pm 1.1$  total days of dietary stabilization.

407  
408 The enrollment and data distillation details can be found **Supplementary Figure 1**. No  
409 participants withdrew from the inpatient portion after enrollment. The same day [ $^{11}\text{C}$ ]raclopride  
410 scan order (fasted scan followed by milkshake scan) was standard across all participants. Of 61  
411 enrolled participants, fasting [ $^{11}\text{C}$ ]raclopride scan data are available for n=56 (n=1 participant  
412 declined, n=2 scans not performed due to tracer production issue, n=2 scans completed but did  
413 not pass quality control on time activity curves). Of n=56 participants with fasting [ $^{11}\text{C}$ ]raclopride  
414 data, post-milkshake [ $^{11}\text{C}$ ]raclopride scan data are available for n=50 (n=3 scans not performed  
415 due to a tracer production issue, n=3 scans completed but images did not pass quality control.  
416 Full PET data for fasting and milkshake [ $^{11}\text{C}$ ]raclopride scans are available on n=50 participants  
417 (**Table 1**). All participants completed structural MRI. All study procedures were approved by the  
418 Institutional Review Board of the National Institute of Diabetes & Digestive & Kidney Diseases  
419 and the NIH Radiation Safety Committee; participants were compensated for their participation.

#### 420 421 **Metabolic Diet**

422 Participants were placed on a standard eucaloric diet (50% carbohydrate, 15% protein, 35% fat)  
423 with daily energy needs calculated using the Mifflin-St Jeor equation and standard activity factor  
424 of 1.5. All meals were prepared in the NIH Clinical Center Nutrition Department Metabolic Kitchen  
425 with all foods and beverages weighed on a gram scale (Mettler Toledo Model MS12001L/03).

426  
427 For the run-in phase, participants were provided with 3-5 days of meals for retrieval from the NIH  
428 Clinical Center and consumed them at home prior to admission. Participants were instructed to  
429 consume all foods and beverages provided. Any food or beverage not consumed was returned  
430 and weighed back. Participants were also instructed to continue their usual caffeine intake in  
431 calorie-free forms (e.g., black coffee, diet soda) and abstain from alcohol during this period. For  
432 any foods or beverages participants consumed that were not part of the standardized run-in diet,  
433 participants were asked to provide a description and amount of what was consumed so that total  
434 daily nutrient intake was captured. The eucaloric standardized outpatient diet was provided for an  
435 average of  $4.5 \pm 1.0$  days (range 0 – 5 days). Due to COVID-19 pandemic precautions, one  
436 participant was admitted without having completed a diet stabilization, and 3 participants  
437 completed some or all of their 3–5-day diet stabilization in the inpatient setting. The remainder of  
438 the full sample (n=57) consumed their stabilization diet as outpatients.

439  
440 During the inpatient phase, participants continued the same diet and were instructed to consume  
441 all foods and beverages provided. All subjects were confined to the NIH Clinical Center metabolic  
442 unit throughout their inpatient stay without access to outside food. Meals were consumed under  
443 observation. Any uneaten food was weighed back, and energy and macronutrients were replaced  
444 at the next available meal as needed. Diets were designed using ProNutra software (version 3.,

445 Viocare, Inc.). No adverse events, harms or unintended effects resulted from provision of  
446 standardized eucaloric diet.

447

#### 448 **Milkshake**

449 A 226 mL vanilla milkshake was prepared by mixing 40 g Vanilla Scandishake dry mix (Aptalis  
450 Pharma, US), 150 g whole milk, and 36 g heavy cream. The resulting milkshake contained a total  
451 of 418 kcals and 7.4 g protein (7.0% of kcal). Total fat was 28.1 g (60% of kcal) of which 14.9 g  
452 was saturated (32.1% of kcal). Total carbohydrate was 34.6 g (33% of kcal) of which 18 g  
453 comprised total sugar (17.2% of kcal), 9.4 g of which were added sugar (9% of kcal).

454

455 The milkshake was served chilled in an opaque (Styrofoam) cup and consumed through a straw  
456 after an extended overnight fast (~17-18 hours) approximately 30 minutes prior to the start of the  
457 second raclopride scan. Participants were allotted 5 minutes to consume the milkshake.

458

459 The energy and macronutrients provided to the participant in other meals on the shake day were  
460 adjusted to account for contents of the high fat shake, so that overall daily energy and  
461 macronutrient intake remained stable in comparison with intake over inpatient stay.

462

#### 463 ***Ad libitum* Lunch Array**

464 The night prior to their last day of inpatient admission, participants fasted between the end of their  
465 dinner (~6:30 pm) and the ad libitum lunch array the following day (~12:00 pm) to mimic time of  
466 day and metabolic conditions surrounding their completed milkshake [<sup>11</sup>C]raclopride scan.  
467 Participants were presented with a standardized buffet lunch meal (>6000 kcals, 35%  
468 carbohydrate, 17% protein, 48% fat) that provided a variety of different foods. Participants were  
469 allowed to consume as much food as desired, with each food weighed before and after  
470 consumption to determine total nutrient intake.

471

472 The array (**Supplementary Figure 6**) consisted of: eight slices of Ultimate Grains Whole Wheat  
473 Bread, 250g roast beef deli meat, 250g turkey deli meat, 220g Glenview Farms Swiss Cheese,  
474 220g Glenview Farms American Cheese, 200g sliced tomatoes, 200g green leaf lettuce, 200g  
475 grapes, 18 Chips Ahoy! Chocolate Chip Cookies, 135g Hellmann's Real Mayonnaise, 135g  
476 Monarch Yellow Mustard, 375g El Pasado Mild Salsa, 200g baby carrots, 180g Tostito Tortilla  
477 Chips, and 850g sterile water. The eight slices of bread and 18 cookies were weighed before  
478 array administration, and the weight was recorded in grams.

479

480 A total of 5 participants data were unavailable or removed from analyses pertaining to ad libitum  
481 intake, leaving 45 participants for analysis (n=2 not collected due to truncated testing schedule  
482 due to pandemic, n=1 data was subject to weigh back error, n=1 scheduling error having  
483 erroneously completed the ad libitum test after consuming fat/sweet taste preloads, and n=1 failed  
484 to disclose a food aversion (wheat bread) prior to the test).

485

486 Energy intake was calculated in total and separately for cookie-only energy intake and non-cookie  
487 energy intake. Total energy intake and sub fractions were adjusted by resting energy expenditure  
488 using the means, residuals, intercept and slope of energy intake (total, cookie, non-cookie) versus  
489 resting energy expenditure for the subsample of participants with available array data (n=45).

490

#### 491 **Taste Testing**

492 Sucrose and fat preference were assessed using a two-series paired comparison-tracking method  
493 developed at the Monell Center for Adults (Coward and Beauchamp 1990, Pepino and Mennella  
494 2007, Mennella, Lukasewycz et al. 2011). Subjects were presented with pairs of solutions differing  
495 in sucrose concentration (3, 6, 12, 24, and 36 g per 100 mL) and pairs of puddings differing in fat

496 concentrations (0, 3.8, 8.4, 19, and 33 percent fat by weight, achieved via dilutions of skim 0% fat  
497 and heavy cream 33% fat in commercially available vanilla pudding powder). They were asked to  
498 taste the samples without swallowing and point to which of the pair they liked better.  
499 Subsequently, each pair presented was determined by the subject's preceding preference choice.  
500 The entire task was then repeated with the stimulus pairs presented in reverse order. After  
501 completion of the taste task, the geometric mean of the preferred concentrations was  
502 determined (Mennella, Finkbeiner et al. 2014, Mennella and Bobowski 2016). For the five sucrose  
503 solutions, the first pair presented was from the middle range (6 and 24% wt/vol), whereas for the  
504 pudding samples, the first pair was the two extremes (3.8 and 19% for fat). All stimuli were  
505 presented at room temperature. One drop of yellow food coloring (McCormick & Co., Inc. Hunt  
506 Valley, MD, USA) was added to the sample to mask color differences.

## 507 Questionnaires

508 The following reflects questionnaire outcomes pertinent to the exploratory analyses presented in  
509 the current study. Other exploratory questionnaire outcomes not included will be reported  
510 elsewhere. All questionnaire data were collected and managed using Research Electronic Data  
511 Capture (REDCap) (Harris, Taylor et al. 2009, Harris, Taylor et al. 2019) electronic data capture  
512 tools hosted at NIDDK.

513 Post-milkshake Ratings. Immediately after consuming the milkshake and prior to their  
514 second and final [<sup>11</sup>C]raclopride scan, participants responded to a series of questions pertaining  
515 to their orosensory and hedonic perception of the milkshake using a visual analog scale (Carlsson  
516 1983) with the following anchors: How pleasant was the milkshake? (0= "Neutral", 100=  
517 "Extremely pleasant"); How much do you want more of the milkshake? (0= "I don't want any more  
518 at all", 100= "I want much more of the milkshake"); How did the milkshake compare to your  
519 expectations? (0= "Worse than I expected", 50= "As I expected", 100= "Better than I expected").

520 Hunger and Satiety Visual Analog Scales. Participants reported their perception of  
521 momentary hunger in the overnight fasted state prior to their first [<sup>11</sup>C]raclopride and immediately  
522 following consumption of the milkshake: "How hungry do you feel ? (0= "I am not hungry at all",  
523 100= "I have never been more hungry").

524 Three Factor Eating Questionnaire (TFEQ). Participants completed the TFEQ, a self-  
525 assessment questionnaire developed to measure eating behavior traits of dietary restraint,  
526 disinhibition and hunger. (Stunkard and Messick 1985) at a standardized time during their inpatient  
527 stay.

528 Yale Food Addiction Scale (YFAS). Participants completed the YFAS, a self-report  
529 questionnaire designed to assess the presence and severity of addictive-like eating of high-fat, high-  
530 sugar foods in the preceding 12 months via items adopted from DSM-IV-R diagnostic criteria for  
531 substance use disorders (Gearhardt, Corbin et al. 2009). Participants reported on the frequency of  
532 problematic behaviors (e.g. "I find that when I start eating certain foods, I end up eating much more  
533 than planned." 0= "Never" through 4= "4 or more times [a week] or daily") at a standardized time  
534 during their inpatient stay. We report the resulting Symptom Count Scores range from 0 – 7,  
535 computed by summing the scores for each of 7 criterion (0= "Criterion not met", 1= "Criterion met").

536 Food Frequency Questionnaire III (DHQIII; National Cancer Institute). Diet history  
537 questionnaire was completed at the initial visit. Participants were instructed to consider intake  
538 over the "past year" and report portion sizes consumed. Analyses included variable labeled  
539 "Added sugars by total sugar NDSR (grams)". Outliers were examined across completed  
540 questionnaires from all enrolled participants (n=56). We applied a conservative outlier rule to  
541 exclude implausible reported intakes ( $Q3 - (IQR * 2.2) = \max$ ;  $Q1 - (IQR * 2.2) = \min$ ) (Hoaglin and  
542 Iglewicz 1987, Burcham, Liu et al. 2023) and three participants were excluded for implausibly high  
543 intake. One participant was removed from the analysis for reporting an intake less than  
544 500kcal/day. A total of 52 eligible dietary histories were eligible for analysis, 45 of which were  
545 from participants with available milkshake PET scanning (pre and post milkshake).



547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597

## **Anthropometrics**

Height was measured in centimeters using a wall stadiometer (Seca 242, Hanover, MD, USA) and weight was measured in kilograms using a digital scale (Scale-Tronix 5702, Carol Steam, IL, USA). All measurements were obtained after an overnight fast while participants were wearing comfortable clothing.

## **Body Composition**

During the inpatient stay, participants each completed one Dual Energy X-Ray Absorptiometry (DEXA) scan while wearing hospital gown/scrubs to determine body composition (General Electric Lunar iDXA; General Electric; Milwaukee, WI, USA).

## **Resting Energy Expenditure**

While inpatient, after a 12 hour overnight fast, participants underwent indirect calorimetry using the ventilated hood technique while supine. Data were collected for 30 minutes and the first 5 minutes were excluded from analysis. Resting energy expenditure was calculated using the principles of indirect calorimetry using the  $VO_2$  and  $VCO_2$  measurements (Weir 1949).

## **Analytical Measurements**

Blood was collected at three timepoints: in the overnight fasted state, 30 minutes post-milkshake, 90 minutes post-milkshake. Blood samples were drawn into chilled EDTA-coated tubes containing preservative (glucose: GLT additive; insulin: SST additive) and kept on ice until centrifuged (1600 g for 15 min at 4°C) within 30 min of collection for isolation of plasma. Samples were processed immediately after collection and portions stored for future measurement of biomarkers. Glucose was analyzed using Hexokinase method assayed on Abbott Architect. Insulin was analyzed using electrochemiluminescence Immunoassay on Roche Cobas e601 analyzer.

Area under the glucose and insulin curves (AUC) were calculated using trapezoidal method. We report on exploratory Metrics of 90-minute weighted average (AUC / 90 minutes), absolute change in values between time points, and peak change from baseline over available data (at either 30 minutes or 90 minutes post milkshake) and present a repeated measures ANOVA with 3 within subjects factors (time) and group membership (whole striatal “Responder” vs “Non-responder”) as between-subject factor (**Supplementary Figure 5**). The HOMA-IR value was calculated as follows:  $[HOMA-IR = \text{fasting glucose (mg/dL)} \times \text{insulin (mcU/L)} / 405]$ .

## **Magnetic Resonance Imaging**

During their inpatient stay, MRI was completed to collect high resolution T-1 weighted structural brain images on which to register individual subject PET data. Due to the duration of data collection, extended by the COVID-19 pandemic, T1 weighted structural MRIs were collected on 3T Siemens Verio (n=21; TE = 2.98 ms, TR = 2.3 ms, TI = 900 ms, flip angle 9°, slice thickness = 1.2 mm, voxel size 1\*1\*1.2mm), and on 3T GE MR-750 Discovery scanner (n=6, TE = 3.04 ms, TR = 7.648 ms, TI = 1060 ms, flip angle 8°, slice thickness = 1.0 mm, voxel size 1\*1\*1mm; n=32, TE= 3.46 ms, TR = 8.156 ms, TI = 900 ms, flip angle 7°, slice thickness = 1.0 mm, voxel size 1\*1\*1 mm) for each subject. Quality of individual subject data were checked by study team [VLD & JG].

The anatomical images were parcellated with FreeSurfer software to generate ROI binary mask volumes in each subject in the putamen, caudate, accumbens, pallidum, and the cerebellum (reference region) (<http://surfer.nmr.mgh.harvard.edu>). All individual ROI masks were visually checked.

## 598 **Positron Emission Tomography**

599 All PET scanning was performed using a High Resolution Research Tomograph (HRRT),  
600 (Siemens Healthcare, Malvern, PA), a dedicated brain PET scanner with resolution of 2.5 - 3.0  
601 mm and a 25 cm axial field of view. Transmission scanning was performed with a <sup>137</sup>Cs rotating  
602 point source scan to correct for attenuation. A bolus of approximately 20 mCi of [<sup>11</sup>C]raclopride  
603 was infused intravenously using a Harvard® pump at both the fasting and post-milkshake scans.  
604

605 The molar activity of [<sup>11</sup>C]raclopride was approximately 4865 mCi/μmol and the radiochemical  
606 purity of the radiotracer was >90%. PET emission data for [<sup>11</sup>C]raclopride were collected starting  
607 at radiotracer injection over one block lasting 75 minutes. Twenty-four frames were acquired in  
608 list mode at times 0, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,  
609 65, 70 min. During each scan block, the room was illuminated and quiet, and each subject was  
610 instructed to keep their head as still as possible, relax, and try to avoid falling asleep. The image  
611 reconstruction process corrected for head motion which was tracked throughout each scan using  
612 an optical head tracking sensor (Polaris Vicra, Northern Digital Inc., Shelburne, VT, USA).  
613

614 Each scan consisted of 207 slices (slice separation = 1.2 mm). The fields of view were 31.2 cm  
615 and 25.2 cm for transverse and axial slices, respectively. The PET images were aligned within  
616 each scan block with 6-parameter rigid registration using 7th order polynomial interpolation and  
617 each block was aligned to the volume taken at 20 min of the first block. The final alignments were  
618 visually checked, with translations varying by <5 mm and the rotations by <5 degrees.  
619

620 For region of interest analyses, individual participants' anatomical MRI images were co-registered  
621 to the aligned PET images by minimizing a mutual information cost function for each individual  
622 participant. Time-activity curves for each tracer concentration in the Freesurfer-generated ROIs  
623 were extracted and kinetic parameters were fit to a two-compartment model (with the cerebellum  
624 used as the reference tissue given negligible D2/3R specific binding (Vandehey, Moirano et al.  
625 2010) to determine regional D2BP (Lammertsma and Hume 1996).  
626

627 For voxelwise analyses, each individual's anatomical MRI was nonlinearly transformed into the  
628 Talairach space using AFNI 3dQwarp, and the transformation matrix was applied to the PET  
629 images which were then smoothed with a 5-mm full-width, half-max Gaussian kernel. Final  
630 coregistration was visually checked. Data were exported from Talairach space to MATLAB where  
631 time-activity curves for tracer concentration in each voxel were fit to a kinetic model using the  
632 cerebellum as a reference tissue to determine D2BP at each voxel and exported back to Talairach  
633 space for group level spatial analyses.  
634

## 635 **Statistics**

636 Power calculations based on 80% of power and 5% of type I error indicated a sample size of 39  
637 participants to detect a nonlinear relationship between fasting striatal D2BP and BMI which was  
638 the first primary aim of this study (Darcey, Guo et al. 2023). To follow up on an exploratory  
639 preliminary finding using n=13 of BMI-dependent dopamine release in the ventral pallidum  
640 (r=0.586; p=0.045), we increased the sample size to 50 distributed evenly across 3 BMI strata to  
641 detect r>0.6 at p<0.05 and > 80% power. Our recruitment exceeded the minimum sample size  
642 requirement. We report here results for the full sample. The much smaller previous studies  
643 showing a dopamine effect suggested that this was more than ample to detect an effect of the  
644 milkshake.  
645

646 Statistical analyses were performed using IBM SPSS Statistics (Version 28.0.1.1, Chicago, IL,  
647 USA). Tests were 2-sided and alpha was set to 0.05. In the ROI analyses, associations between  
648 either BMI or percent body fat and percent change in D2BP between fasting and milkshake scans

649 were evaluated with regression analyses. Person correlation coefficients were also reported.  
650 Robustness of associations was tested using SPSS extension for Robust Regression.

651  
652 In the voxel-wise analyses, regional clusters where D2BP's are highly correlated with BMI were  
653 identified with regression analysis in AFNI's 3dttest++ (<https://afni.nimh.nih.gov/>). Since high  
654 D2BP occurs mainly in striatum, small volume corrections were implemented within each  
655 hemisphere where D2BP >1.5. A bi-sided uncorrected voxel-wise threshold of p<0.1 was used  
656 with a cluster extent minimum of 20 voxels (faces touching). Resultant clusters were deemed to  
657 survive correction for multiple comparisons using 3dClustSim at alpha of <0.05 and a threshold  
658 of 34 voxels.

### 659 **Keywords**

661 Obesity, controlled-feeding, ultra-processed, dopamine, [<sup>11</sup>C]raclopride, PET, striatum

### 662 **Study Approval**

664 All study procedures were approved by the Institutional Review Board of the National Institute of  
665 Diabetes & Digestive & Kidney Diseases and the NIH Radiation Safety Committee. Written  
666 informed consent was received prior to participation and compensation was provided.

### 667 **References**

- 669  
670 Benowitz, N. L. (2010). "Nicotine addiction." *N Engl J Med* **362**(24): 2295-2303.  
671 Breier, A., T.-P. Su, R. Saunders, R. Carson, B. Kolachana, A. de Bartolomeis, D. Weinberger, N.  
672 Weisenfeld, A. Malhotra and W. Eckelman (1997). "Schizophrenia is associated with elevated  
673 amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron  
674 emission tomography method." *Proceedings of the National Academy of Sciences* **94**(6): 2569-  
675 2574.  
676 Burcham, S., Y. Liu, A. L. Merianos and A. Mendy (2023). "Outliers in nutrient intake data for  
677 U.S. adults: national health and nutrition examination survey 2017-2018." *Epidemiol Methods*  
678 **12**(1): 20230018.  
679 Burger, K. S. and E. Stice (2012). "Frequent ice cream consumption is associated with reduced  
680 striatal response to receipt of an ice cream-based milkshake." *The American journal of clinical*  
681 *nutrition* **95**(4): 810-817.  
682 Cárdenas, L., S. Houle, S. Kapur and U. E. Busto (2004). "Oral D-amphetamine causes prolonged  
683 displacement of [<sup>11</sup>C]raclopride as measured by PET." *Synapse* **51**(1): 27-31.  
684 Carlsson, A. M. (1983). "Assessment of chronic pain. I. Aspects of the reliability and validity of  
685 the visual analogue scale." *Pain* **16**(1): 87-101.  
686 Carnell, S., K. E. Steele, G. Thapaliya, H. Kuwubara, A. Aghababian, A. Papantoni, A. Nandi, J. R.  
687 Brašić, T. H. Moran and D. F. Wong (2023). "Milkshake Acutely Stimulates Dopamine Release in  
688 Ventral and Dorsal Striatum in Healthy-Weight Individuals and Patients with Severe Obesity  
689 Undergoing Bariatric Surgery: A Pilot Study." *Nutrients* **15**(12): 2671.  
690 Carroll, M. E. (1985). "The role of food deprivation in the maintenance and reinstatement of  
691 cocaine-seeking behavior in rats." *Drug and Alcohol Dependence* **16**(2): 95-109.  
692 Chen, E. Y. and T. A. Zeffiro (2020). "Hunger and BMI modulate neural responses to sweet  
693 stimuli: fMRI meta-analysis." *International Journal of Obesity* **44**(8): 1636-1652.

694 Chukwueke, C. C. and B. Le Foll (2019). Tobacco and Positron-Emission Tomography (PET) of the  
695 Dopaminergic System: A Review of Human Studies. Neuroscience of Nicotine: Mechanisms and  
696 Treatment, Elsevier: 107-117.

697 Cowart, B. and G. Beauchamp (1990). "Early development of taste perception." Psychological  
698 basis of sensory evaluation: 1-17.

699 Darcey, V. L., J. Guo, M. Chi, S. T. Chung, A. B. Courville, I. Gallagher, P. Herscovitch, R. Howard,  
700 M. LaNoire, L. Milley, A. Schick, M. Stagliano, S. Turner, N. Urbanski, S. Yang, E. Yim, N. Zhai, M.  
701 S. Zhou and K. D. Hall (2023). "Striatal dopamine tone is positively associated with body mass  
702 index in humans as determined by PET using dual dopamine type-2 receptor antagonist  
703 tracers." medRxiv: 2023.2009.2027.23296169.

704 DiFeliceantonio, A. G., G. Coppin, L. Rigoux, S. Edwin Thanarajah, A. Dagher, M. Tittgemeyer and  
705 D. M. Small (2018). "Supra-Additive Effects of Combining Fat and Carbohydrate on Food  
706 Reward." Cell Metabolism **0**(0): 1-12.

707 Doudet, D. J. and J. E. Holden (2003). "Sequential versus nonsequential measurement of density  
708 and affinity of dopamine D2 receptors with [<sup>11</sup>C]raclopride: effect of methamphetamine." J  
709 Cereb Blood Flow Metab **23**(12): 1489-1494.

710 Drevets, W. C., J. C. Price, D. J. Kupfer, P. E. Kinahan, B. Lopresti, D. Holt and C. Mathis (1999).  
711 "PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum."  
712 Neuropsychopharmacology **21**(6): 694-709.

713 Eisenstein, S. A., K. J. Black, A. Samara, J. M. Koller, J. P. Dunn, T. Hershey, S. Klein and G. I.  
714 Smith (2020). "Striatal Dopamine Responses to Feeding are Altered in People with Obesity."  
715 Obesity (Silver Spring, Md.) **28**(4): 765-765.

716 Endres, C. J., B. S. Kolachana, R. C. Saunders, T. Su, D. Weinberger, A. Breier, W. C. Eckelman  
717 and R. E. Carson (1997). "Kinetic Modeling of [<sup>11</sup>C]Raclopride: Combined PET-Microdialysis  
718 Studies." Journal of Cerebral Blood Flow & Metabolism **17**(9): 932-942.

719 Fazzino, T. L., K. Rohde and D. K. Sullivan (2019). "Hyper-Palatable Foods: Development of a  
720 Quantitative Definition and Application to the US Food System Database." Obesity (Silver  
721 Spring) **27**(11): 1761-1768.

722 Fernandes, A. B., J. A. da Silva, J. Almeida, G. Cui, C. R. Gerfen, R. M. Costa and A. J. Oliveira-  
723 Maia (2020). "Postingestive modulation of food seeking depends on vagus-mediated dopamine  
724 neuron activity." Neuron **106**(5): 778-788. e776.

725 Ferreira, J. G., L. A. Tellez, X. Ren, C. W. Yeckel and I. E. de Araujo (2012). "Regulation of fat  
726 intake in the absence of flavour signalling." The Journal of physiology **590**(4): 953-972.

727 Gearhardt, A. N., N. B. Bueno, A. G. DiFeliceantonio, C. A. Roberto, S. Jiménez-Murcia and F.  
728 Fernandez-Aranda (2023). "Social, clinical, and policy implications of ultra-processed food  
729 addiction." BMJ **383**: e075354.

730 Gearhardt, A. N., W. R. Corbin and K. D. Brownell (2009). "Preliminary validation of the Yale  
731 food addiction scale." Appetite **52**(2): 430-436.

732 Hajnal, A., G. P. Smith and R. Norgren (2004). "Oral sucrose stimulation increases accumbens  
733 dopamine in the rat." Am J Physiol Regul Integr Comp Physiol **286**(1): R31-37.

734 Han, W., Luis A. Tellez, J. Niu, S. Medina, Tatiana L. Ferreira, X. Zhang, J. Su, J. Tong, Gary J.  
735 Schwartz, A. van den Pol and Ivan E. de Araujo (2016). "Striatal Dopamine Links Gastrointestinal  
736 Rerouting to Altered Sweet Appetite." Cell Metabolism **23**(1): 103-112.

737 Harada, N., S. Nishiyama, K. Satoh, D. Fukumoto, T. Kakiuchi and H. Tsukada (2002). "Age-  
738 related changes in the striatal dopaminergic system in the living brain: a multiparametric PET  
739 study in conscious monkeys." Synapse **45**(1): 38-45.

740 Harris, P. A., R. Taylor, B. L. Minor, V. Elliott, M. Fernandez, L. O'Neal, L. McLeod, G. Delacqua, F.  
741 Delacqua, J. Kirby and S. N. Duda (2019). "The REDCap consortium: Building an international  
742 community of software platform partners." Journal of Biomedical Informatics **95**: 103208.

743 Harris, P. A., R. Taylor, R. Thielke, J. Payne, N. Gonzalez and J. G. Conde (2009). "Research  
744 electronic data capture (REDCap)—A metadata-driven methodology and workflow process for  
745 providing translational research informatics support." Journal of Biomedical Informatics **42**(2):  
746 377-381.

747 Hirvonen, J., S. Aalto, V. Lumme, K. Någren, J. Kajander, H. Vilkmann, N. Hagelberg, V. Oikonen  
748 and J. Hietala (2003). "Measurement of striatal and thalamic dopamine D2 receptor binding  
749 with <sup>11</sup>C-raclopride." Nucl Med Commun **24**(12): 1207-1214.

750 Hoaglin, D. C. and B. Iglewicz (1987). "Fine-tuning some resistant rules for outlier labeling."  
751 Journal of the American Statistical Association **82**(400): 1147-1149.

752 Johnson, P. M. and P. J. Kenny (2010). "Dopamine D2 receptors in addiction-like reward  
753 dysfunction and compulsive eating in obese rats." Nature Neuroscience **13**(5): 635-641.

754 Lammertsma, A. A. and S. P. Hume (1996). "Simplified reference tissue model for PET receptor  
755 studies." Neuroimage **4**(3 Pt 1): 153-158.

756 Laruelle, M., R. N. Iyer, M. S. Al-Tikriti, Y. Zea-Ponce, R. Malison, S. S. Zoghbi, R. M. Baldwin, H.  
757 F. Kung, D. S. Charney and P. B. Hoffer (1997). "Microdialysis and SPECT measurements of  
758 amphetamine-induced dopamine release in nonhuman primates." Synapse **25**(1): 1-14.

759 Marengo, S., R. E. Carson, K. F. Berman, P. Herscovitch and D. R. Weinberger (2004). "Nicotine-  
760 induced dopamine release in primates measured with [<sup>11</sup>C]raclopride PET."  
761 Neuropsychopharmacology **29**(2): 259-268.

762 Martínez Steele, E., L. G. Baraldi, M. L. d. C. Louzada, J.-C. Moubarac, D. Mozaffarian and C. A.  
763 Monteiro (2016). "Ultra-processed foods and added sugars in the US diet: evidence from a  
764 nationally representative cross-sectional study." BMJ Open **6**(3): e009892.

765 McDougale, M., A. de Araujo, A. Singh, M. Yang, I. Braga, V. Paille, R. Mendez-Hernandez, M.  
766 Vergara, L. N. Woodie, A. Gour, A. Sharma, N. Urs, B. Warren and G. de Lartigue (2024).  
767 "Separate gut-brain circuits for fat and sugar reinforcement combine to promote overeating."  
768 Cell Metab **36**(2): 393-407.e397.

769 Mennella, J. A. and N. K. Bobowski (2016). "Psychophysical Tracking Method to Measure Taste  
770 Preferences in Children and Adults." J Vis Exp(113).

771 Mennella, J. A., S. Finkbeiner, S. V. Lipchock, L. D. Hwang and D. R. Reed (2014). "Preferences  
772 for salty and sweet tastes are elevated and related to each other during childhood." PLoS One  
773 **9**(3): e92201.

774 Mennella, J. A., L. D. Lukasewycz, J. W. Griffith and G. K. Beauchamp (2011). "Evaluation of the  
775 Monell forced-choice, paired-comparison tracking procedure for determining sweet taste  
776 preferences across the lifespan." Chem Senses **36**(4): 345-355.

777 Morris, E. D. and K. K. Yoder (2007). "Positron Emission Tomography Displacement Sensitivity:  
778 Predicting Binding Potential Change for Positron Emission Tomography Tracers Based on Their  
779 Kinetic Characteristics." Journal of Cerebral Blood Flow & Metabolism **27**(3): 606-617.

- 780 Nordström, A.-L., L. Farde, S. Pauli, J.-E. Litton and C. Halldin (1992). "PET analysis of central [11  
781 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age  
782 effects." Human Psychopharmacology: Clinical and Experimental **7**(3): 157-165.
- 783 Okabe, T., H. Terashima and A. Sakamoto (2015). "Determinants of liquid gastric emptying:  
784 comparisons between milk and isocalorically adjusted clear fluids." Br J Anaesth **114**(1): 77-82.
- 785 Oldfield, R. C. (1971). "The assessment and analysis of handedness: The Edinburgh inventory."  
786 Neuropsychologia **9**(1): 97-113.
- 787 Pauli, W. M., R. C. O'Reilly, T. Yarkoni and T. D. Wager (2016). "Regional specialization within  
788 the human striatum for diverse psychological functions." Proc Natl Acad Sci U S A **113**(7): 1907-  
789 1912.
- 790 Pepino, M. Y. and J. A. Mennella (2007). "Effects of Cigarette Smoking and Family History of  
791 Alcoholism on Sweet Taste Perception and Food Cravings in Women." Alcohol Clin Exp Res  
792 **31**(11): 1891-1899.
- 793 Schiffer, W. K., N. D. Volkow, J. S. Fowler, D. L. Alexoff, J. Logan and S. L. Dewey (2006).  
794 "Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and  
795 extracellular dopamine." Synapse **59**(4): 243-251.
- 796 Schultz, W., P. Dayan and P. R. Montague (1997). "A neural substrate of prediction and reward."  
797 Science **275**(5306): 1593-1599.
- 798 Small, D. M. and A. G. DiFeliceantonio (2019). "Processed foods and food reward." Science  
799 **363**(6425): 346-347.
- 800 Small, D. M., M. Jones-Gotman and A. Dagher (2003). "Feeding-induced dopamine release in  
801 dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers."  
802 NeuroImage **19**(4): 1709-1715.
- 803 Stice, E., K. S. Burger and S. Yokum (2013). "Relative ability of fat and sugar tastes to activate  
804 reward, gustatory, and somatosensory regions." The American Journal of Clinical Nutrition  
805 **98**(6): 1377-1384.
- 806 Stice, E., S. Spoor, C. Bohon and D. M. Small (2008). "Relation between obesity and blunted  
807 striatal response to food is moderated by TaqIA A1 allele." Science **322**(5900): 449-452.
- 808 Stice, E., S. Yokum, K. Blum and C. Bohon (2010). "Weight gain is associated with reduced  
809 striatal response to palatable food." Journal of Neuroscience **30**(39): 13105-13109.
- 810 Stunkard, A. J. and S. Messick (1985). "The three-factor eating questionnaire to measure dietary  
811 restraint, disinhibition and hunger." Journal of Psychosomatic Research **29**(1): 71-83.
- 812 Tellez, L. A., W. Han, X. Zhang, T. L. Ferreira, I. O. Perez, S. J. Shammah-Lagnado, A. N. Van Den  
813 Pol and I. E. De Araujo (2016). "Separate circuitries encode the hedonic and nutritional values of  
814 sugar." Nature Neuroscience **19**(3): 465-470.
- 815 Tellez, L. A., S. Medina, W. Han, J. G. Ferreira, P. Licona-Limón, X. Ren, T. K. T. Lam, G. J.  
816 Schwartz and I. E. De Araujo (2013). "A gut lipid messenger links excess dietary fat to dopamine  
817 deficiency." Science **341**(6147): 800-802.
- 818 Thanarajah, S. E., H. Backes, A. G. DiFeliceantonio, K. Albus, A. L. Cremer, R. Hanssen, R. N.  
819 Lippert, O. A. Cornely, D. M. Small, J. C. Brüning and M. Tittgemeyer (2018). "Food Intake  
820 Recruits Orosensory and Post-ingestive Dopaminergic Circuits to Affect Eating Desire in  
821 Humans." Cell metabolism **0**(0).
- 822 Tomasi, D., P. Manza, J. Logan, E. Shokri-Kojori, M. V. Yonga, D. Kroll, D. Feldman, K.  
823 McPherson, C. Biesecker, E. Dennis, A. Johnson, K. Yuan, W. T. Wang, J. A. Butman, G. J. Wang

824 and N. D. Volkow (2023). "Time-varying SUVr reflects the dynamics of dopamine increases  
825 during methylphenidate challenges in humans." Commun Biol **6**(1): 166.

826 Tsukada, H., S. Nishiyama, T. Kakiuchi, H. Ohba, K. Sato and N. Harada (1999). "Is synaptic  
827 dopamine concentration the exclusive factor which alters the in vivo binding of  
828 [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys." Brain Res  
829 **841**(1-2): 160-169.

830 van Galen, K. A., A. Schranke, K. W. ter Horst, S. E. la Fleur, J. Booij, R. T. Constable, G. J.  
831 Schwartz, R. J. DiLeone and M. J. Serlie (2023). "Brain responses to nutrients are severely  
832 impaired and not reversed by weight loss in humans with obesity: a randomized crossover  
833 study." Nature Metabolism **5**(6): 1059-1072.

834 Vandehey, N. T., J. M. Moirano, A. K. Converse, J. E. Holden, J. Mukherjee, D. Murali, R. J.  
835 Nickles, R. J. Davidson, M. L. Schneider and B. T. Christian (2010). "High-affinity dopamine  
836 D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal  
837 regions using a multiple-injection protocol." J Cereb Blood Flow Metab **30**(5): 994-1007.

838 Volkow, N. D., J. S. Fowler, G.-J. Wang, S. L. Dewey, D. Schlyer, R. MacGregor, J. Logan, D.  
839 Alexoff, C. Shea and R. Hitzemann (1993). "Reproducibility of repeated measures of carbon-11-  
840 raclopride binding in the human brain." Journal of Nuclear Medicine **34**(4): 609-613.

841 Volkow, N. D., G. J. Wang, J. S. Fowler, J. Logan, D. Schlyer, R. Hitzemann, J. Lieberman, B.  
842 Angrist, N. Pappas and R. MacGregor (1994). "Imaging endogenous dopamine competition with  
843 [11C] raclopride in the human brain." Synapse **16**(4): 255-262.

844 Wang, G.-J., D. Tomasi, A. Convit, J. Logan, C. T. Wong, E. Shumay, J. S. Fowler and N. D. Volkow  
845 (2014). "BMI Modulates Calorie-Dependent Dopamine Changes in Accumbens from Glucose  
846 Intake." PLoS ONE **9**(7): e101585-e101585.

847 Wang, G. J., C. E. Wiers, E. Shumay, D. Tomasi, K. Yuan, C. T. Wong, J. Logan, J. S. Fowler and N.  
848 D. Volkow (2019). "Expectation effects on brain dopamine responses to methylphenidate in  
849 cocaine use disorder." Translational Psychiatry **9**(1): 93-93.

850 Weir, J. B. d. V. (1949). "New methods for calculating metabolic rate with special reference to  
851 protein metabolism." J Physiol **109**(1-2): 1-9.

852 Wise, R. A. and M. A. Robble (2020). "Dopamine and Addiction." Annu Rev Psychol **71**: 79-106.  
853